Skip to main content
. 2021 Dec 3;12:760737. doi: 10.3389/fimmu.2021.760737

Figure 3.

Figure 3

Safety profiles based on adverse events (A) and immune-related adverse events (B). Pooled incidences and 95% confidence intervals of grade 1–5 events for each treatment are at bottom and that of grade 3–5 events are at top of the figure. Each cell of the safety profiles contains the pooled relative risks and 95% confidence intervals for grade 1–5 (light gray cell) and grade 3–5 (dark gray cell) events; significant results are in bold. The pooled relative risks and 95% confidence intervals indicate the results of the top treatment compared with the bottom treatment. ICI, immune checkpoint inhibitor; n, number.